Izencitinib Explained

Izencitinib (TD-1473) is a drug which acts as a pan-Janus kinase inhibitor, binding with high affinity at all three subtypes JAK1, JAK2 and JAK3. It is taken orally and was developed to be gut selective with minimal absorption into the rest of the body, allowing targeting of inflammatory bowel disease but with reduced side effects compared to other similar drugs.[1] [2]

See also

Notes and References

  1. Roda G, Dal Buono A, Argollo M, Danese S . JAK selectivity: more precision less troubles . Expert Review of Gastroenterology & Hepatology . 14 . 9 . 789–796 . September 2020 . 32520647 . 10.1080/17474124.2020.1780120 .
  2. Hardwick RN, Brassil P, Badagnani I, Perkins K, Obedencio GP, Kim AS, Conner MW, Bourdet DL, Harstad EB . Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species . Toxicological Sciences . 186 . 2 . 323–337 . March 2022 . 35134999 . 10.1093/toxsci/kfac002 . 8963331 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Izencitinib".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.